{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:10:15Z","timestamp":1790251815966,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03089-9","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:15:49Z","timestamp":1786367749000},"page":"2368-2371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BTK inhibitors are associated with a lower risk of myeloid neoplasms and non-melanoma skin cancer compared with chemoimmunotherapy in chronic lymphocytic leukemia: a propensity score\u2013matched analysis"],"prefix":"10.1038","volume":"40","author":[{"given":"Pratik","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9918-7959","authenticated-orcid":false,"given":"Yu-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu Hsien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan Ping","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Hung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-6161","authenticated-orcid":false,"given":"Cho-Han","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"3089_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00784-z","volume":"13","author":"L van der Straten","year":"2023","unstructured":"van der Straten L, Levin MD, Dinnessen MAW, Visser O, Posthuma EFM, Doorduijn JK, et al. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989\u20132019. Blood Cancer J. 2023;13:15.","journal-title":"Blood Cancer J"},{"key":"3089_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0237-1","volume":"9","author":"V Kumar","year":"2019","unstructured":"Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019;9:75.","journal-title":"Blood Cancer J"},{"key":"3089_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/bjh.17337","volume":"193","author":"C da Cunha-Bang","year":"2021","unstructured":"da Cunha-Bang C, Rostgaard K, Andersen MA, Rotbain EC, Gr\u00f8nb\u00e6k K, Frederiksen H, et al. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study. Br J Haematol. 2021;193:339\u201345.","journal-title":"Br J Haematol"},{"key":"3089_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102307","volume":"65","author":"T Chatzikonstantinou","year":"2023","unstructured":"Chatzikonstantinou T, Scarf\u00f2 L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, et al. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. EClinicalMedicine. 2023;65:102307.","journal-title":"EClinicalMedicine"},{"key":"3089_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390:326\u201337.","journal-title":"N Engl J Med"},{"key":"3089_CR6","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa2504341","volume":"393","author":"T Munir","year":"2025","unstructured":"Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, et al. Measurable residual disease\u2013guided therapy for chronic lymphocytic leukemia. N Engl J Med. 2025;393:1177\u201390.","journal-title":"N Engl J Med"},{"key":"3089_CR7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739\u201354.","journal-title":"N Engl J Med"},{"key":"3089_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","volume":"25","author":"M F\u00fcrstenau","year":"2024","unstructured":"F\u00fcrstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2024;25:744\u201359.","journal-title":"Lancet Oncol"},{"key":"3089_CR9","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","volume":"26","author":"JR Anderson","year":"2008","unstructured":"Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26:3913\u20135.","journal-title":"J Clin Oncol"},{"key":"3089_CR10","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127:3052\u201364.","journal-title":"J Clin Invest"},{"key":"3089_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/imj.16445","volume":"54","author":"D Baggio","year":"2024","unstructured":"Baggio D, Chung E, Wellard C, Waters N, Cushion T, Chong G, et al. Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era. Intern Med J. 2024;54:1223\u20137.","journal-title":"Intern Med J"},{"key":"3089_CR12","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","volume":"131","author":"D Rossi","year":"2018","unstructured":"Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131:2761\u201372.","journal-title":"Blood"},{"key":"3089_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamadermatol.2021.2856","volume":"157","author":"N Anand","year":"2021","unstructured":"Anand N, Edwards L, Baker LX, Chren M, Wheless L. Validity of using billing codes from electronic health records to estimate skin cancer counts. JAMA Dermatol. 2021;157:1089\u201394.","journal-title":"JAMA Dermatol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03089-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:26Z","timestamp":1790250206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03089-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3089"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03089-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study used deidentified data from the TriNetX Global Collaborative Network and did not involve direct patient contact or access to identifiable private information. Institutional review board approval and informed consent were therefore not required in accordance with applicable institutional policy.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Artificial intelligence was used solely to assist with language editing, including grammar, sentence structure, clarity, and overall manuscript flow. The AI tool was not used to generate scientific content, perform data analysis, influence study design, or contribute to data interpretation or study conclusions. All content was reviewed and approved by the authors, who take full responsibility for the accuracy and integrity of the manuscript. Editing assistance was provided using ChatGPT, based on a GPT-5 family large language model (OpenAI, San Francisco, CA, USA), accessed via the ChatGPT web interface.","order":3,"name":"Ethics","label":"Artificial intelligence statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}